Sanofi: positive preclinical evaluation, Covid-19
(CercleFinance.com) - Sanofi Pasteur and Translate Bio, a specialist in messenger RNA (mRNA) therapeutics, announce that the preclinical evaluation of their candidate vaccine, MRT5500, has shown a favourable immune response profile against SARS-CoV-2.
Based on this evaluation, two doses of MRT5500 induced the production of neutralising antibody concentrations significantly higher than those observed in patients infected by the Covid-19 virus.
“These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020” said the two partners.
Copyright (c) 2020 CercleFinance.com. All rights reserved.